“showed a trend”

Among CC FD metrics, both uncorrected CC FD total area and proportional area showed a trend toward increase during 24 months follow-up with nAMD development (p = 0.053 and p = 0.053, respectively; Table 4 and Figure 4 ).

Notably, the frequency of GZMB + CD4 cytotoxic T cells showed a trend to be elevated (p = 0.053, Kruskal-Wallis test including multiple-group correction) already on D1 ( Figure S3 H).

In patients who were given chemotherapy, high LAIR-1 expression showed a trend of shorter patient survival (HR = 1.0, 95% CI 0.8–1.6, p = 0.053: Figure 4 A).

The performance on the discrimination index of the novel object and the displaced object showed a trend between groups [NOR: F (3, 36) = 2.818, p = 0.053], SOR: [ F (3, 34) = 2.775, p = 0.056].

Patients with uric acid stones showed a trend toward statistical significance with 534 days versus 602 days for calcium oxalate stones ( p = 0.053).

The Parallel task showed a trend toward a significant difference [ F (1,65) = 3.883, p = 0.053, partial η 2 = 0.056].

In our cohort, PDAC showed a trend toward lower CR-POPF rates compared to non-PDAC cases (29.1 % vs. 44.0 %, p = 0.053), although this did not reach significance in multivariable analysis ( p = 0.722).

Lymphovascular invasion (LVI) and pN1 showed a trend toward poor DFS (LVI, p=0.053; pN1, p=0.059).

Multivariable Cox Proportional Hazards Regression In multivariable Cox proportional hazards regression analysis adjusting for age, sex, and level of obstruction, secretory obstruction (vs structural obstruction) showed a trend toward lower failure risk in the secretory group compared with the structural group (HR, 0.28; 95% CI, 0.077–1.015; p = 0.053) ( Table 3 ; Supplementary Figure S1 ). 4.

Similarly, in a dataset of 110 ovarian cancer patients who received cisplatin chemotherapy, high SLFN11 expression showed a trend associated with longer OS (p = 0.053).

In multivariate analyses, the female sex was independently associated with reduced all‐cause death (aHR 0.59; 95% CI 0.38–0.91, p = 0.019) and showed a trend toward higher AFDAS risk (aHR 1.57; 95% CI 0.99–2.49, p = 0.053).

In the glutamine supplemented group, milk glutamate content showed a trend ( P = 0.053) to be higher at 7 days post farrowing than at parturition.

Univariate analyses using the cox regression analysis ( Tables S1 – S5 ) revealed that recurrence was a significant prognosticator for PFS (HR, 3.986; 95% CI: 1.246–12.754, p = 0.020); salvage IMRT is a significant predictor for PFS (HR, 3.009; 95% CI: 1.007–8.991, p = 0.049); the use of ENI significantly improves LPFS (HR, 0.136; 95% CI: 0.019–0.964, p = 0.046); recurrence showed a trend to predict DMFS (HR, 5.373; 95% CI: 0.981–29.426, p = 0.053), and OS (HR, 5.886; 95% CI: 0.931–37.231, p = 0.060); salvage IMRT showed a trend to predict LPFS (HR, 5.840; 95% CI: 0.821–41.522, p = 0.078).

3.95 ± 0.73 mm/m 2 , p = 0.004), while its correlation with aging showed a trend toward statistical significance (R = −0.057, p = 0.053).

This showed a trend‐level association with SIS ( B = −0.413, SE = 0.210, β = −0.217, p = 0.053), indicating that the association between Risk and SIS was strongest when Rescue values were low.

RESULTS/ANTICIPATED RESULTS: Comparison of the 1D MRS results from the OGM of male with CPPS and male controls only showed a trend of reducing concentration of N‐acetyl (NAA)/creatine (Cr)+PCr in males with CPSS ( p = 0.053).

Weighted mode MR also showed a trend toward reduced risks of hip OA (OR = 0.89, 95% CI: 0.80–1.00, P = 0.053).

Letrozole 0.5 mg showed a trend (p=0.053) towards a survival benefit. 21 The second study included 551 patients.

Lambda (the path length normalised for network size and connectivity), as a measure of global network integration, showed a trend for a difference in trajectories over the 24-week study period in the beta band (MMRM, F(2,279) = 2.97, p = 0.053; ICC = 0.083) (See Table 4 and Figure 5 ).

An analysis in the subgroup without diabetes showed a trend toward an improvement in the primary endpoint in the morphine group (22.5% [14–33] vs. 27.5% [22–41], p = 0.053).

We found a significant association between antibody positivity status (0, 1, or ≥2 antibodies) and self-identified gender, while mpox seropositivity (≥2 antibodies positive) showed a trend toward increased prevalence among males compared to females [10/129 (7.8%) vs. 1/85 (1.2%), p = 0.053].

Glucose levels showed a trend toward correlation with age ( r = 0.22, p = 0.053; Figure 2c ) but no significant sex difference ( p = 0.46; Figure 2f ) or correlation with chlorpromazine equivalents ( r = 0.11, p = 0.36; Figure 2i ), while they were significantly correlated with imipramine equivalents ( r = 0.29, p = 0.034; Figure 2l ).

However, CLP-CBG mice showed a trend toward a faster heart rate compared to control CLP mice ( P = .053), with a significant treatment × time effect ( P = .006).

Among the male patients with AMI, peak CRP count showed a trend toward marking the lowest T levels in multivariable analysis (CRP 0.940, OR 0.880–1.000, p = 0.053; WBC 1.210, OR 0.700–2.080, p = 0.501).

Intravenous agents (Cangrelor/GPi) showed a trend towards lower risk of intraprocedural stent occlusion compared to oral dAPT (adjusted odds ratio [aOR] 0.30, [95% CI, 0.09–1.01], P = .053), though this did not reach statistical significance.